Cargando…
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616202/ https://www.ncbi.nlm.nih.gov/pubmed/37903774 http://dx.doi.org/10.1038/s41523-023-00596-1 |
| _version_ | 1785129341344022528 |
|---|---|
| author | Fabi, Alessandra Carbognin, Luisa Botticelli, Andrea Paris, Ida Fuso, Paolo Savastano, Maria Cristina La Verde, Nicla Strina, Carla Pedersini, Rebecca Guarino, Stefania Curigliano, Giuseppe Criscitiello, Carmen Raffaele, Mimma Beano, Alessandra Franco, Antonio Valerio, Maria Rosaria Verderame, Francesco Fontana, Andrea Haspinger, Eva Regina Caldara, Alessia Di Leone, Alba Tortora, Giampaolo Giannarelli, Diana Scambia, Giovanni |
| author_facet | Fabi, Alessandra Carbognin, Luisa Botticelli, Andrea Paris, Ida Fuso, Paolo Savastano, Maria Cristina La Verde, Nicla Strina, Carla Pedersini, Rebecca Guarino, Stefania Curigliano, Giuseppe Criscitiello, Carmen Raffaele, Mimma Beano, Alessandra Franco, Antonio Valerio, Maria Rosaria Verderame, Francesco Fontana, Andrea Haspinger, Eva Regina Caldara, Alessia Di Leone, Alba Tortora, Giampaolo Giannarelli, Diana Scambia, Giovanni |
| author_sort | Fabi, Alessandra |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10616202 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106162022023-11-01 Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer Fabi, Alessandra Carbognin, Luisa Botticelli, Andrea Paris, Ida Fuso, Paolo Savastano, Maria Cristina La Verde, Nicla Strina, Carla Pedersini, Rebecca Guarino, Stefania Curigliano, Giuseppe Criscitiello, Carmen Raffaele, Mimma Beano, Alessandra Franco, Antonio Valerio, Maria Rosaria Verderame, Francesco Fontana, Andrea Haspinger, Eva Regina Caldara, Alessia Di Leone, Alba Tortora, Giampaolo Giannarelli, Diana Scambia, Giovanni NPJ Breast Cancer Author Correction Nature Publishing Group UK 2023-10-30 /pmc/articles/PMC10616202/ /pubmed/37903774 http://dx.doi.org/10.1038/s41523-023-00596-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Fabi, Alessandra Carbognin, Luisa Botticelli, Andrea Paris, Ida Fuso, Paolo Savastano, Maria Cristina La Verde, Nicla Strina, Carla Pedersini, Rebecca Guarino, Stefania Curigliano, Giuseppe Criscitiello, Carmen Raffaele, Mimma Beano, Alessandra Franco, Antonio Valerio, Maria Rosaria Verderame, Francesco Fontana, Andrea Haspinger, Eva Regina Caldara, Alessia Di Leone, Alba Tortora, Giampaolo Giannarelli, Diana Scambia, Giovanni Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer |
| title | Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer |
| title_full | Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer |
| title_fullStr | Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer |
| title_full_unstemmed | Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer |
| title_short | Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer |
| title_sort | author correction: real-world anastase study of atezolizumab+nab-paclitaxel as first-line treatment of pd-l1-positive metastatic triple-negative breast cancer |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616202/ https://www.ncbi.nlm.nih.gov/pubmed/37903774 http://dx.doi.org/10.1038/s41523-023-00596-1 |
| work_keys_str_mv | AT fabialessandra authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT carbogninluisa authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT botticelliandrea authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT parisida authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT fusopaolo authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT savastanomariacristina authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT laverdenicla authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT strinacarla authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT pedersinirebecca authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT guarinostefania authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT curiglianogiuseppe authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT criscitiellocarmen authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT raffaelemimma authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT beanoalessandra authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT francoantonio authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT valeriomariarosaria authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT verderamefrancesco authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT fontanaandrea authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT haspingerevaregina authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT caldaraalessia authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT dileonealba authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT tortoragiampaolo authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT giannarellidiana authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer AT scambiagiovanni authorcorrectionrealworldanastasestudyofatezolizumabnabpaclitaxelasfirstlinetreatmentofpdl1positivemetastatictriplenegativebreastcancer |